NCT07054684View on ClinicalTrials.gov

Study of BHV-1400 in IgA Nephropathy

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
IgA Nephropathy
Interventions
DRUG

BHV-1400

BHV-1400 is delivered subcutaneously (SC)

Trial Locations (6)

33016

RECRUITING

Site-003, Miami Lakes

33029

RECRUITING

Site-005, Pembroke Pines

57049

RECRUITING

Site-002, Dakota Dunes

60521

RECRUITING

Site-009, Hinsdale

63017

RECRUITING

Site-006, Chesterfield

77099

RECRUITING

Site-004, Houston

Sponsors
All Listed Sponsors
lead

Biohaven Therapeutics Ltd.

INDUSTRY

NCT07054684 - Study of BHV-1400 in IgA Nephropathy | Biotech Hunter | Biotech Hunter